Aspira Women's Health Files 8-K on Financials
Ticker: AWHL · Form: 8-K · Filed: Aug 12, 2024 · CIK: 926617
Sentiment: neutral
Topics: financial-reporting, 8-K, company-history
TL;DR
Aspira Women's Health dropped an 8-K detailing its financial situation.
AI Summary
Aspira Women's Health Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This filing provides investors with crucial updates on Aspira Women's Health's financial performance and condition, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing reporting on financial condition and results of operations, not indicating immediate significant risk.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- August 12, 2024 (date) — Date of earliest event reported
- Vermillion, Inc. (company) — Former company name
- Ciphergen Biosystems Inc (company) — Former company name
- Abiotic Systems (company) — Former company name
- Austin, Texas (location) — Company headquarters
FAQ
What specific financial information is being reported in this 8-K?
The 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 12, 2024.
What is the primary business of Aspira Women's Health Inc. according to the filing?
The filing lists the Standard Industrial Classification as 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]'.
What are some of the former names of Aspira Women's Health Inc.?
The company was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.
Where is Aspira Women's Health Inc. headquartered?
The company is headquartered at 12117 Bee Caves Road Building III Suite 100, Austin, Texas.
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-08-12 16:12:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Stock Mark
Filing Documents
- awh-20240812.htm (8-K) — 39KB
- awh-ex99_1.htm (EX-99.1) — 246KB
- img245972787_0.jpg (GRAPHIC) — 132KB
- img245972787_1.jpg (GRAPHIC) — 15KB
- 0000950170-24-095439.txt ( ) — 615KB
- awh-20240812.xsd (EX-101.SCH) — 25KB
- awh-20240812_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2024, Aspira Women's Health Inc. (the "Company") issued a press release reporting financial results for the three and six months ended June 30, 2024. A copy of the Company's press release is attached hereto as Exhibit 99.1. The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Aspira Women's Health on August 12, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: August 12, 2024 By: /s/ Nicole Sandford Nicole Sandford, Chief Executive Officer